Cadila Healthcare stock jumped nearly 4% today after Zydus Cadila received final nod from the USFDA to market Fingolimod capsules. The share gained up to 3.99% to Rs 432.20 against previous close of Rs 415.60 on BSE.
The nod has been given for the strength of 0.5 mg. The share trades higher than 20 day, 50 day, 100 day and 200 day moving averages but lower than 5 day moving averages.
It has gained 84% in one year and 69.37% since the beginning of this year.
Total 1.66 lakh shares changed hands amounting to turnover of Rs 7.08 crore on BSE.
Later, Cadila Healthcare share closed 3.60% or Rs 15 higher at Rs 430.55. The share stands 4.04% away from 52 week high of Rs 447.95
According to the regulatory filing, Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Fingolimod will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Cadila also bagged the final approval from the USFDA to market Verapamil Hydrochloride Injection USP, 5 mg/2 mL (2.5 mg/mL) and 10 mg/4 mL (2.5 mg/mL), Single-Dose Vials(US RLD: Isoptin Injection).
On Verapamil, Cadila said, the injections will be manufactured at the company's manufacturing facility at Jarod, near Vadodara (formerly known as Liva Pharmaceuticals). Verapamil injection is used to rapidly or temporarily restore normal heartbeats in people with certain heart rhythm disorders.
Copyright©2021 Living Media India Limited. For reprint rights: Syndications Today